Summary.-Material with a molecular weight of less than 105 daltons has been isolated and partially purified from the ascitic fluid of DBA2 mice bearing a syngeneic lymphoma (SL2). This substance inhibits the cytotoxic action of an allogeneic antiserum directed specifically against SL2 cells. Material has been rendered radioactive with 1251 and between 20 and 25% of the radioactivity is bound in a specific manner to the antiserum. The material which is referred to as 1251-TSTA has been used in a radioimmunoassay to measure the level of TSTA in the sera of mice bearing both ascitic and subcutaneous SL2 tumours. The level of circulating TSTA was found to be high immediately following inoculation of live SL2 cells, probably because a large proportion of the injected cells autolyse. The serum concentration of TSTA then falls but 6-10 days later begins to rise again in parallel with the growth of the SL2 tumour either in the peritoneal cavity or subcutaneously.
Summary.-Material with a molecular weight of less than 105 daltons has been isolated and partially purified from the ascitic fluid of DBA2 mice bearing a syngeneic lymphoma (SL2). This substance inhibits the cytotoxic action of an allogeneic antiserum directed specifically against SL2 cells. Material has been rendered radioactive with 1251 and between 20 and 25% of the radioactivity is bound in a specific manner to the antiserum. The material which is referred to as 1251-TSTA has been used in a radioimmunoassay to measure the level of TSTA in the sera of mice bearing both ascitic and subcutaneous SL2 tumours. The level of circulating TSTA was found to be high immediately following inoculation of live SL2 cells, probably because a large proportion of the injected cells autolyse. The serum concentration of TSTA then falls but 6-10 days later begins to rise again in parallel with the growth of the SL2 tumour either in the peritoneal cavity or subcutaneously.
Following surgical removal of an intradermal SL2 tumour the level of TSTA in the serum falls rapidly. No evidence could be found that a significant proportion of the TSTA in the serum of tumour-bearing mice is completed with antibody. However, in the serum of DBA2 mice which have been hyperimmunized with irradiated SL2 cells there are antibodies which bind 1251-TSTA although syngeneic anti-SL2 sera, unlike alloantisera, do not show complement dependent lysis of SL2 cells.
A MACROMOLECULAR substance which neutralized a specific allogeneic antiserum raised against the SL2 murine lymphoma was isolated and partially purified from the ascitic fluid of syngeneic (DBA/2) mice bearing the tumour (Wolf and Steele, 1975) . The SL2 lymphoma arose spontaneously in a DBA/2 mouse and while it can be transplanted in the syngeneic host with less than 10 cells, resistance to it can be induced by immunization with irradiated cells. Complement dependent cytotoxicity could not be detected in sera from immunized syngeneic mice but antisera raised in C57/B1 mice to antibody (anti-DBA/2) coated SL2 cells were lytic for SL2 cells after absorption with normal DBA/2 cells. Using this antiserum and the purified antigen labelled with 1251, a radioimmunoassay was developed and used to follow antigenic activity in the sera of mice at different stages of growth of the SL2 lymphoma. While it has not yet been clearly established whether this antigenic material can induce specific resistance in vivo to SL2 cells, the fact that it neutralizes a lytic allogeneic antiserum and, as shown in this paper, combines with hyperimmune syngeneic serum makes it likely that the material is a tumour specific transplantation-type antigen and we refer to it in the text as a " TSTA ".
MATERIALS AND METHODS
Tumours.-The SL2 is a spontaneous DBA/2 lymphoma (Wolf, Barfoot and Johnson, 1972 (Wolf and Steele, 1975) .
Soluble membrane extracts.-Papain digests from membranes derived from SL2 cells, TLX cells and normal DBA/2 lymphoid cells were prepared as described by Sanderson and Welsh (1972) . They were purified by ammonium sulphate fractionation and chromatography on Biogel as used for isolating TSTA from ascitic fluid (Fig. 1) .
Mleasurement of TSTA activity. Inhibition by fractionated material of the cytolytic effect of the specific allogeneic antiserum was used to monitor the TSTA activity throughout the preparation procedure as described by Wolf and Steele (1975) . A conventional complement-dependent cytotoxic method based upon the release of 51Cr from specific target cells was employed (Wigzell, 1965) . The protein content of TSTA preparations was estimated by a modification of the Lowry method (Lowry et al., 1951) .
Murine antisera.-Details on titre and specificity of the allogeneic anti-SL2 serum have been published earlier (Wolf and Steele, 1975 (0.5 mCi) and 25 ,ul chloramine-T (4 mg/ml phosphate buffer). After 6 min of shaking, 25 ,ul of sodium metabisulphite (12 mg/ml) and 100 ,u potassium iodide (100 mg/ml), both in PBS, were added, the latter solution containing 0-50 0 bovine serum albumin (BSA). The mixture was then filtered through a Sephadex G-25 column and labelled antigen separated from free iodine. BSA was added to a final concentration of 10%.
Radioimrnunoassayss.-Assays were carried out using (with slight modifications) the double antibody method according to Egan et al. (1972 Inhibitory tests were performed in a similar way except for the pre-incubation of the unlabelled material with the diluted specific antiserum. Ten 1l of the unlabelled preparations were incubated 18-24 h with a constant amount of the appropriately diluted specific antiserum at 4°C. Ten ,ul of labelled antigen in BSA-PBS were then added 3-5 h before the addition of the precipitating serum. The assay was then continued as before.
Results from radioimmunoassays were expressed either as percent of total counts added (in titrations) or as the percent of the maximal precipitable radioactivity by the used serum dilution (in displacement assays with unlabelled materials). TSTA activity in sera from tumour-bearing animals was expressed as inhibition, i. Fig. 1 (revised procedure) and represents a, slight variation from the method previously described (Wolf and Steele, 1975) , in that chromatography on DEAE cellulose was introduced earlier in the separation procedure rather than as the last step (original procedure). This was done because occasionally activity could not be eluted from the DEAE column when the antigen was applied in a relatively purified form. This problem was obviated in the revised procedure which gave better yields but the specific activity (Wolf and Steele, 1975) of the radioactivity eluted in fractions corresponding to a molecular weight greater than 105 daltons. The remainder eluted in the 5 X 104 to 105 molecular weight range and this was considered to be non-aggregated antigen and is referred to as TSTA-G2. TSTA-CM was used in the radioimmunoassays but TSTA-G2 had to be employed to demonstrate binding to the antiserum by chromatography (see below). Sanderson, 1974) .
Specificity of the radioimmunoassay
Titration experiments.-The details of the radioimmunoassay are described in Materials and Methods. The procedure employs 2 antibodies (Egan et al., 1972) . The anti-TSTA antibody (derived from C57/B1 mice immunized with SL2) is reacted with 1251-labelled TSTA and then an excess of rabbit anti-mouse IgG is added so as to precipitate all of the specific IgG together with the bound 125I-TSTA. Figure 5 shows titration experiments in which 1251-TSTA preparations containing approximately 2 X 104 ct/min in 10 ,al were added to dilutions of immune and control mouse sera. The fraction of the radioactivity which was precipitated on the addition of the rabbit anti-mouse IgG was counted and found to be for the allogeneic antiserum and both TSTA-DEAE 2 and TSTA-CM between 30 and 35%o, whereas the syngeneic hyperimmune serum precipitated approximately 28%. A background of 8-10 % unspecific precipitation was noted in these titration experiments.
Displacement experiments.-The amount of TSTA in a specimen is calculated from the quantity of 1251-TSTA it displaces from the precipitate which consists of the reference amount of 1251-TSTA and the specific alloantiserum at the optimum dilution for sensitivity, found in our system to be 1: 250. Figure  6 shows displacement carried out with papain extracts from different cells and Fig. 7 displacement by different TSTAs. Materials extracted from normal DBA2 spleen cells and from the unrelated lymphoma TLX9 (neither cells being lysed by the absorbed specific antiserum) do not inhibit the binding of 1251-TSTA significantly, whereas a similar extract from SL2 cells does. Figure 7 shows experiments with fractions 2 and 4 of the DEAE column as described earlier (Wolf and Steele, 1975) and the preparation TSTA-CM described in this paper. Figure 7 illustrates that the TSTA-DEAE-2 and TSTA-CM, both of which are potent inhibitors of the cytotoxic allogeneic antiserum, also produce significant displacement in the radioimmunoassay and that they inhibit more than TSTA-DEAE-4 which is also relatively inactive in the neutralization of lytic capacity. Fig. 6 andl the text.
mice and from DBA/2 mice bearing the SL2 lymphoma were assayed to find the most suitable dilution for the inhibition tests described below. As can be seen in Fig. 8 , a dilution of 1 : 100 was satisfactory. Sera from tumour-bearing mice were diluted 1: 100 and the percent inhibition of binding of 1251-TSTA was determined. Figure 9 illustrates that at Day 1 after i.p. inoculation of the tumour a high level of TSTA activity can be detected in the serum. This level then declines and reaches a minimum at Day 6, after which it rises again and continues to increase until the animals die, which is approximately on DaY 14. Figure 9 further shows that when a different preparation of 1251-TSTA was used for assaying the same samples of animals with an ascitic tumour the same pattern of serum TSTA activity was observed.
An attempt was then made to determine whether part of the TSTA in the sera of these tumour-bearing mice was bound to antibody formed in response to the growing tumour. The sera were treated by a procedure which would be expected to dissociated syngeneic anti-TSTA activity in the serumn of tumour bearing mice Preliminary experiments were carried out in which sera from normal DBA/2 Serum Dilution body from antigen. * Figure 9 shows that there was no significant difference in the capacity of lower (i.e. less than 1 05 daltons) molecular weight material and the untreated sera to compete for 1251-TSTA. This suggests that the proportion of antigen liberated into the circulation which is bound by antibody is small or non-existent. Figure 10 illustrates 2 experiments in which the level of TSTA activity was measured in mice carrying a subcutaneously growing SL2 lymphoma. The 2 experiments were carried out with 2 different preparations of 1251-TSTA, and, as in the case of the ascitic tumours, qualitatively similar results were obtained with the 2 antigen preparations. The pattern of TSTA activity is also similar to that seen for the ascitic tumours, in that immediately after inoculation high values are found. These then drop and rise again as the tumour grows. However, after the growing tumour has been removed surgically (which is possible since the SL2 lymphoma does not disseminate readily) the level of circulating TSTA activity rapidly declines (Fig. 10) .
A series of control experiments was performed in which sera were taken from mice bearing the unrelated TLX9 lymphoma which is not lysed by the alloantisera. At no time was any significant TSTA activity detected in the sera, of such mice. On the other hand, sera from mice bearing the L 5178 Y lymphoma showed anti-TSTA activity although this was less than that observed with mice bearing the SL2 lymphoma, and appears to reflect the partial cross-reactivity between these 2 DBA/2 tumours (cf. Materials and Methods).
Antibody activity in the seritm of syngeneic mice hyperimmunized with irradiated
SL2 cells
During the course of these studies some experiments were carried out using syngeneic hyperimmune sera. Although DBA/2 mice can be rendered resistant to a challenge with SL2 cells by irradiated SL2 cells (cf. Materials and Methods) their sera are not cYtotoxic to SL2 cells in vitro with either weanling rabbit or guinea-pig complement. This absence of cytotoxicity of the hyperimmunie syngeneic sera is in marked contrast to the absorbed allogeneic antiserum, which is lytic to SL2 cells up to a titre of 1: 900 in the 51Cr release method (Wolf and Steele, 1975) . However, the hyperimmune syngeneic serum and the allogeneic antiserum both bind 1251-TSTA although the syngeneic serum binds slightly less than the latter. Binding is shown in * The sera were exposed to pH 3-1 and filtered through an Amicon membrane XM-100 in order to dissilve possible immune complexes and separate material of 105 and less mol. wt. from all the higher mol. wt. material (Thomson et al., 1973 It is noteworthy that the procedures used for the radioimmunoassay in this study and in the rat sarcoma investigations were very different in that (1) the source and the procedure used for the isolation and purification of the TSTA were quite dissimilar; (2) the specific antiserum in the sarcoma experiments was derived from syngeneic animals as opposed to the absorbed alloantiserum employed in the present study; (3) the radioimmunoassay in the sarcoma studies involved binding to insolubilized antiserum as opposed to precipitation by a xenogeneic anti-mouse IgG in the SL2 experiments. That both studies showed a similar pattern for the changes in the blood levels of TSTA during tumour growth gives confidence that the observations are genuine.
The present assay is not sufficiently precise to determine whether the serum of tumour bearing mice contains antibodies that bind soluble TSTA. However, the finding that there is no significant increase in the level of TSTA in sera after they have been treated so as to dissociate possible antigen-antibody complexes indicates that at most a small fraction of the TSTA released by the growing tumour is complexed with antibody. Nonetheless, it would appear that the DBA2 mice are capable of producing antibodies directed against the TSTA of SL2 lymphoma since the serum from DBA2 mice which have been hyperimmunized with irradiated SL2 cells binds the 1251-TSTA isolated from the ascitic fluid. An interesting finding is that this hyperimmune serum does not lyse SL2 cells in the presence of complement and studies are in progress to determine the immunoglobulin classes of this antiserum.
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